Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01235845
Recruitment Status : Unknown
Verified November 2010 by Qingdao University.
Recruitment status was:  Not yet recruiting
First Posted : November 8, 2010
Last Update Posted : December 3, 2010
Information provided by:
Qingdao University

November 5, 2010
November 8, 2010
December 3, 2010
January 2011
December 2012   (Final data collection date for primary outcome measure)
To assess the survival of malignant glioma [ Time Frame: 1 year ]
Same as current
Complete list of historical versions of study NCT01235845 on Archive Site
To assess the immune response of patients, to assess progression free survival and to evaluate quality of life. [ Time Frame: 1 year ]
Same as current
Not Provided
Not Provided
Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma
A Phase I/II Clinical Trial Evaluating DC Activated Cytokine-induced Killer Cell(DCIK) Combined With DC Treatment for Glioma

Malignant gliomas are very aggressive and among the most common of brain tumors. A diagnosis carries with it a median survival of approximately 12 months, with 90 - 95% of patients surviving less than 2 years. The current standard treatment of surgical resection followed by radiation therapy and chemotherapy has not substantially prolonged survival.

Dendritic cells (DCs) are immune cells that form part of the mammalian immune system. Their main function is to process antigen material and present it on the surface to other cells of the immune system, thus functioning as antigen-presenting cells.In the present study, DCs were used for antigen presentation of glioma antigens to directly induce a cytotoxic T-cell response. Cytokine-induced killer (CIK)cells are shown to be a heterogeneous population, and the major population expresses both the T cell marker CD3 and the NK cell marker CD56, and is termed NKT cells, which has shown significant anti-tumor activity in both clinical trials and animal studies.

Furthermore, CIK cells are able to expand significantly when they are cultured with DCs, and the CIK cells activated by DCs stimulation (DCIKs)have a characteristic which cytotoxic activity enhanced and show increased anti-tumor activity.

This study aimed to evaluate the clinical efficacy of DCIK cells treatment combined with DCs following tumor resection and radiotherapy in patients with malignant glioma.

Not Provided
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Malignant Glioma
Biological: Biological: DC activated CIK combined with DC

Dendritic cells pulsed With tumor lysate were injected back into the patient intradermally close to a lymph node, DC vaccinations will be given every week for a total of four vaccinations.

DC activated CIK combined with IL-2 were injected intratumorally via an Ommaya reservoir every week for a total of two vaccinations.

Experimental: DC-DCIK
Intervention: Biological: Biological: DC activated CIK combined with DC
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
September 2013
December 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Female or male, adult patients of 18 to 70 years of age at time of diagnosis that qualify for standard treatment including surgery and radiotherapy.
  2. Histologically confirmed diagnosis of 1 of the following malignant gliomas:

    Anaplastic astrocytoma Glioblastoma multiforme Oligodendroglioma Oligoastrocytoma

  3. Newly diagnosed or recurrent disease
  4. Patients must have had surgical resection at UCLA for the collection of their tumor. Total, subtotal, or partial resection of more then 70% of tumor mass defined by MRI.
  5. After surgery, a pathological diagnosis of malignant glioma (WHO Grade III or IV) will need to be established.
  6. Supratentorial tumour localisation.
  7. Karnofsky performance status 60-100%
  8. Life expectancy ≥ 12 weeks
  9. Written informed consent of patient and/or legal guardian.
  10. Must be off of steroid at least two weeks prior to vaccination
  11. Hematologic and metabolic panel results will be within the parameters of the protocol.
  12. Negative pregnancy test
  13. Fertile patients must use effective contraception
  14. Hepatitis B negative
  15. Hepatitis C negative
  16. HIV negative
  17. Syphilis serology negative
  18. Patient must have no prior sensitivity to the components of the dendritic cell vaccine.

Exclusion Criteria:

  1. Anti-neoplastic chemotherapy or radiotherapy during 4 weeks before entering the study,
  2. Presence of acute infection
  3. Inability to obtain informed consent because of psychiatric or complicating medical problems.
  4. Unstable or severe intercurrent medical or psychiatric conditions as determined by the Investigator.
  5. Subjects with organ allografts.
  6. Contraindication to MRI
  7. Known history of autoimmune disorder
  8. Subjects who have an uncontrolled systemic malignancy that is not in remission.
  9. Pregnancy or breast-feeding.
  10. Positive for hepatitis B, C, HIV, syphilis
  11. Patients unwilling to perform a save method of birth control.
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Yao Weicheng, Dou Yihe, Gao Hong, Jiao Yingbin, Zhang Xuefeng, Stemcell center of the affiliated hospital of medical colledge,Qingdao university
Qingdao University
Not Provided
Study Chair: Weicheng Yao 2010 year
Qingdao University
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP